NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»21/10/2009 [Industry news]
China Biologic Products Named to Forbes Magazine Fifth Annual List of Asia\'s 200 Best Under a Billion

China Biologic Products, Inc. one of the leading plasma-based pharmaceutical companies in China, today announced that the Company was named on Forbes Magazine\'s fifth annual list of Asia\'s \"200 Best Under a Billion\" for the year 2009.

 
China Biologic Products, Inc. one of the leading plasma-based pharmaceutical companies in China, today announced that the Company was named on Forbes Magazine\'s fifth annual list of Asia\'s \"200 Best Under a Billion\" for the year 2009. To assemble its Best Under a Billion for the Asia-Pacific region, Forbes considered only listed entities with under $1 billion in sales that have posted solid top and bottom-line gains and appear to be headed for more. The 200 Asia-Pacific companies were selected based on their: profitability, growth, modest indebtedness and future prospects this year (for a more precise methodology, go online to http://www.forbes.com/BUB ). According to Forbes, this year\'s selection were survivors of unprecedented dislocations in the global economy over the past 12 months, disrupted supply chains, frozen lines of credit, depleted consumer coffers and business spending hibernation, who seized opportunities rising from the economic uncertainty. China Biologic was one of only 78 companies in China and Hong Kong to make the prestigious list. \"We are pleased that Forbes Magazine has recognized China Biologic as one of the Asia-Pacific region\'s best small and mid-sized companies,\" said Mr. Chao Ming Zhao, the Company\'s Chief Executive Officer. \"We believe that this accolade reflects our strong financial performance as well as our position as the leading non-state owned, plasma-based biopharmaceutical company in China.\"

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.